September 20, 2017 3:14 PM ET


Company Overview of MaSTherCell S.A.

Company Overview

MaSTherCell S.A. specializes in contract-based manufacturing services focusing on cellular therapy products and technologies. It offers cell-based ATMPs (advanced therapy medicinal products) and HCT/Ps (human cell, tissue, and cellular and tissue-based products). The company has strategic partnerships with Aseptic Technologies, Immune Health, Artelis, and Quality Assistance S.A. MaSTherCell S.A. was founded in 2011 and is based in Gosselies, Belgium. As of February 27, 2015, MaSTherCell S.A. operates as a subsidiary of Orgenesis Inc.

48, Rue Auguste Piccard

Gosselies,  6041


Founded in 2011


32 7 134 76 29

Key Executives for MaSTherCell S.A.

MaSTherCell S.A. does not have any Key Executives recorded.

MaSTherCell S.A. Key Developments

MaSTherCell S.A. Announces Management Changes

On July 6, 2017, Mr. Hugues Bultot resigned from the position of Chief Executive Officer and Managing Director of MaSTherCell S.A. Mr. Bultot’s resignation became effective as of July 11, 2017. Mr. Bultot will continue to serve as Director on the Board of Directors of MaSTherCell and the Company. On July 6, 2017, the Board of directors of MaSTherCell appointed Denis Bedoret, Ph.D. as General Manager and day-to-day Manager of MaSTherCell, effective as of July 11, 2017. Dr. Bedoret, Age 37, joined MaSTherCell in October 2016 as Chief Business and Administration Officer.

CRISPR Therapeutics and MaSTherCell SA Sign Service Agreement for the Development and Manufacturing of Allogeneic Cell Therapies

CRISPR Therapeutics AG and MaSTherCell SA announced the signing of an agreement to develop and manufacture allogeneic CAR-T therapies. MaSTherCell will be responsible for the development and cGMP manufacturing of CTX101 for use in clinical studies. CTX101 is an allogeneic CAR T-cell therapy currently in development by CRISPR Therapeutics for the treatment of CD19 positive malignancies. The program utilizes CRIPSR's proprietary gene-editing technology to make targeted modifications to the T-cell, thereby enabling an allogeneic, or off-the-shelf, product that is applicable to a broader patient population and addresses the industrialization challenges of the current generation of autologous therapies. MaSTherCell provides process optimization and manufacturing services to cell therapy organizations. It has quickly built the most extensive experience in the field and is focused on developing solutions to the industrialization challenges facing the cell therapy sector.

CRISPR Therapeutics AG Enters into Allogeneic Cell Therapy Development and Manufacturing Deal with MaSTherCell SA

CRISPR Therapeutics AG has entered into an agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. Under the deal, MaSTherCell will be responsible for development and cGMP manufacturing of CTX101 for use in clinical studies.

Similar Private Companies By Industry

Company Name Region
ADx NeuroSciences NV Europe
Apitope International NV Europe
Beta-Cell NV Europe
Bienca S.A. Europe
Biopole S.A. Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Tax Management Inc United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MaSTherCell S.A., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at